Spyre Therapeutics, Inc. - Common Stock, par value $0.0001 per share (SYRE) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2023 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
SYRE on Nasdaq
Shares outstanding
78,841,667
Price per share
$33.36
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
80,976,878
Total reported value
$2,652,563,796
% of total 13F portfolios
0%
Share change
+15,502,207
Value change
+$541,005,178
Number of holders
152
Price from insider filings
$33.36
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Spyre Therapeutics, Inc. - Common Stock, par value $0.0001 per share (SYRE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Fairmount Funds Management LLC 10% $136,033,480 8,106,882 Peter Evan Harwin 15 Oct 2025
BlackRock, Inc. 6.6% $59,323,024 3,962,635 BlackRock, Inc. 30 Jun 2025
RTW INVESTMENTS, LP 6.2% $54,402,380 3,621,996 RTW Investments, LP 31 Dec 2024
VANGUARD GROUP INC 5.1% $45,907,406 3,066,586 The Vanguard Group 30 Jun 2025
Venrock Healthcare Capital Partners III, L.P. 4.6% $40,335,429 2,685,448 Venrock Healthcare Capital Partners III, L.P. 31 Dec 2024
PERCEPTIVE ADVISORS LLC 4.4% -56% $38,672,339 -$185,961,697 2,574,723 -80% Perceptive Advisors LLC 31 Dec 2024
TANG CAPITAL MANAGEMENT LLC 2.4% -58% $62,064,160 -$42,895,840 1,892,200 -41% TANG CAPITAL MANAGEMENT, LLC 31 Dec 2025

As of 31 Dec 2025, 152 institutional investors reported holding 80,976,878 shares of Spyre Therapeutics, Inc. - Common Stock, par value $0.0001 per share (SYRE). This represents 103% of the company’s total 78,841,667 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Spyre Therapeutics, Inc. - Common Stock, par value $0.0001 per share (SYRE) together control 87% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 15% 11,638,819 +28% 0.02% $381,287,711
BlackRock, Inc. 7% 5,522,101 +39% 0% $180,904,030
RTW INVESTMENTS, LP 5.3% 4,171,996 +15% 1.4% $136,674,589
VANGUARD GROUP INC 5.1% 4,035,074 +32% 0% $132,189,024
Fairmount Funds Management LLC 5.1% 4,018,101 0% 10% $131,632,989
VR ADVISER, LLC 4.7% 3,685,448 +37% 6% $120,735,276
Capital International Investors 4.4% 3,492,541 +46% 0.02% $114,415,643
PERCEPTIVE ADVISORS LLC 3.9% 3,069,225 +150% 1.8% $100,547,811
Driehaus Capital Management LLC 3.7% 2,882,420 +40% 0.64% $94,428,079
Commodore Capital LP 3% 2,388,245 +20% 5.2% $78,238,906
STATE STREET CORP 2.9% 2,262,839 +27% 0% $74,130,606
TCG Crossover Management, LLC 2.4% 1,900,582 +73% 2.1% $62,263,066
TANG CAPITAL MANAGEMENT LLC 2.4% 1,892,200 -41% 3.1% $61,988,472
JANUS HENDERSON GROUP PLC 2.3% 1,829,009 +13969% 0.03% $59,918,335
GEODE CAPITAL MANAGEMENT, LLC 2.1% 1,659,140 +35% 0% $54,362,088
BRAIDWELL LP 2.1% 1,634,615 -37% 1.7% $53,549,987
RA CAPITAL MANAGEMENT, L.P. 2.1% 1,621,620 0.55% $53,124,271
PRICE T ROWE ASSOCIATES INC /MD/ 2% 1,601,882 +158% 0.01% $52,479,000
WELLINGTON MANAGEMENT GROUP LLP 2% 1,549,284 -5.5% 0.01% $50,754,544
Paradigm Biocapital Advisors LP 1.9% 1,467,266 0% 1.3% $48,067,634
Remedium Capital Partners, LLC 1.8% 1,456,231 0% 28% $47,706,000
Affinity Asset Advisors, LLC 1.8% 1,432,591 +0.94% 3.4% $46,931,681
FRANKLIN RESOURCES INC 1.4% 1,109,274 +39% 0.01% $36,339,817
BAKER BROS. ADVISORS LP 1.3% 1,000,000 0% 0.19% $32,760,000
Pictet Asset Management Holding SA 1.2% 913,960 -12% 0.03% $29,941,330

Institutional Holders of Spyre Therapeutics, Inc. - Common Stock, par value $0.0001 per share (SYRE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 80,976,878 $2,652,563,796 +$541,005,178 $32.76 152
2025 Q3 64,298,657 $1,077,601,900 +$12,200,602 $16.76 136
2025 Q2 63,624,754 $952,552,077 +$19,485,332 $14.97 128
2025 Q1 62,108,053 $1,004,204,799 +$22,237,875 $16.14 128
2024 Q4 59,883,954 $1,394,038,124 +$171,655,898 $23.28 129
2024 Q3 51,375,323 $1,511,815,633 +$36,820,905 $29.41 118
2024 Q2 50,382,939 $1,184,222,119 +$421,575,660 $23.51 106
2024 Q1 31,640,426 $1,196,964,043 +$172,560,163 $37.93 101
2023 Q4 28,010,905 $600,997,673 +$524,495,293 $21.52 54
2023 Q3 3,257,983 $39,909,852 +$39,909,852 $12.25 27